------------------------------
OMB APPROVAL
------------------------------
OMB Number:
Expires:
Estimated average burden
hours per response ....... 0.5
------------------------------
U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 3
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or
Section 20(f) of the Investment Company Act of 1949
(Print or Type Responses)
________________________________________________________________________________
1. Name and Address of Reporting Person
OrbiMed Advisors LLC
--------------------------------------------------------------------------------
(Last) (First) (Middle)
767 Third Avenue, 6th Floor
--------------------------------------------------------------------------------
(Street)
New York New York 10010
--------------------------------------------------------------------------------
(City) (State) (Zip)
________________________________________________________________________________
2. Date of Event Requiring Statement (Month/Day/Year)
September 8, 2000
________________________________________________________________________________
3. IRS Identification Number of Reporting Person, if an Entity (Voluntary)
________________________________________________________________________________
4. Issuer Name and Ticker or Trading Symbol
Enchira Biotechnology Corporation ("ENBC")
________________________________________________________________________________
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
[ ] Director [X] 10% Owner
[ ] Officer (give title below) [ ] Other (specify below)
________________________________________________________________________________
6. If Amendment, Date of Original (Month/Day/Year)
________________________________________________________________________________
7. Individual or Joint/Group Filing (Check applicable line)
[_] Form Filed by One Reporting Person
[_] Form Filed by More than One Reporting Person
================================================================================
Table I -- Non-Derivative Securities Beneficially Owned
================================================================================
<TABLE>
<CAPTION>
3. Ownership Form:
2. Amount of Securities Direct (D) or
1. Title of Security Beneficially Owned Indirect (I) 4. Nature of Indirect Beneficial Ownership
(Instr. 4) (Instr. 4) (Instr. 5) (Instr. 5)
------------------------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C>
Common Stock 410,000 shares I for Caduceus Capital Trust
------------------------------------------------------------------------------------------------------------------------------------
Common Stock 210,000 shares I for Caduceus Capital II, L.P.
------------------------------------------------------------------------------------------------------------------------------------
Common Stock 600,000 shares I for PaineWebber Eucalyptus Fund, LLC
------------------------------------------------------------------------------------------------------------------------------------
Common Stock 35,000 shares I for PaineWebber Eucalyptus Fund, Ltd.
====================================================================================================================================
</TABLE>
Reminder: Report on a separate line for each class of securities beneficially
owned directly or indirectly.
Page 1 of 4
<PAGE>
Table II -- Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
================================================================================
<TABLE>
<CAPTION>
3. Title and Amount 5. Owner-
of Securities ship
Underlying Derivative Form of
2. Date Exercisable Security (Instr. 4) Derivative
and Expiration Date ------------------------ 4. Conver- Security:
(Month/Day/Year) Amount sion or Direct 6. Nature of
1. Title of ---------------------- or Exercise (D) or Indirect
Derivative Date Expira- Number Price of Indirect Beneficial
Security Exer- tion of Derivative (I) Ownership
(Instr. 4) cisable Date Title Shares Security (Instr. 5) (Instr. 5)
------------------------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C> <C> <C>
------------------------------------------------------------------------------------------------------------------------------------
warrants 9/8/00 9/8/02 common stock 123,600 $7.44 I for Cadeceus Capital Trust
------------------------------------------------------------------------------------------------------------------------------------
warrants 9/8/00 9/8/02 common stock 63,000 $7.44 I for Cadeceus Capital II, L.P.
------------------------------------------------------------------------------------------------------------------------------------
warrants 9/8/00 9/8/02 common stock 180,000 $7.44 I for PaineWebber Eucalyptus Fund, LLC
------------------------------------------------------------------------------------------------------------------------------------
warrants 9/8/00 9/8/02 common stock 10,500 $7.44 I for PaineWebber Eucalyptus Fund, Ltd.
====================================================================================================================================
</TABLE>
Explanation of Responses:
** Intentional misstatements or omissions of fact constitute Federal Criminal
Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Orbimed Advisors LLC
By: /s/ Samuel D. Isaly October 16, 2000
-------------------------------- ----------------
Name: Samuel D. Isaly Date
Title: Managing Member
** Signature of Reporting Person
Note: File three copies of this Form, one of which must be manually signed.
If space provided is insufficient, See Instruction 6 for procedure.
Page 2 of 4
<PAGE>
Other Reporting Persons
Designated Filer - OrbiMed Advisors LLC
Date of Event - 9/8/00
Issuer - Enchira Biotechnology Corporation ("ENBC")
Caduceus Capital Trust
c/o OrbiMed Advisors LLC
767 Third Avenue, 6th Floor
New York, NY 10010
Caduceus Capital II, L.P.
c/o OrbiMed Advisors LLC
767 Third Avenue, 6th Floor
New York, NY 10010
PaineWebber Eucalyptus Fund, LLC
c/o OrbiMed Advisors LLC
767 Third Avenue, 6th Floor
New York, NY 10010
PaineWebber Eucalyptus Fund, Ltd.
c/o OrbiMed Advisors LLC
767 Third Avenue, 6th Floor
New York, NY 10010
Page 3 of 4
<PAGE>
Signature Page for Other Reporting Persons
Caduceus Capital Trust
By: /s/ Samuel D. Isaly
--------------------------
Name: Samuel D. Isaly
Title: Portfolio Manager
Caduceus Capital II, L.P.
By: /s/ Samuel D. Isaly
--------------------------
Name: Samuel D. Isaly
Title: Portfolio Manager
PaineWebber Eucalyptus Fund, LLC
By: /s/ Samuel D. Isaly
--------------------------
Name: Samuel D. Isaly
Title: Portfolio Manager
PaineWebber Eucalyptus Fund, Ltd.
By: /s/ Samuel D. Isaly
--------------------------
Name: Samuel D. Isaly
Title: Portfolio Manager
Page 4 of 4
